earnings
confidence high
sentiment positive
materiality 0.60
Celularity reports 2024 revenue of $54.2M, up 138% YoY; operating loss narrows 80%
Celularity Inc
2025-Q1 EPS
reported -$0.84
vs consensus -$0.77
▼ miss
(-9.8%)
- Net revenues $54.2M, up 138.1% YoY; product sales in wound care up 168.7% to $35.3M.
- Operating expenses fell 57% to $92.6M; loss from operations improved 80.1% to $38.4M.
- Received FDA Tissue Reference Group recommendation letters for new placental-derived biomaterial products.
- Cash and cash equivalents $738K at Dec 31, 2024, up from $227K prior year.
- Total assets $132.7M; stockholders' equity $8.8M at year-end 2024.